Ardelyx, Inc. (ARDX) income statement
ARDXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3058% below fair value
$3.12−0.06 (-1.89%)
Close on Nov 18, 2026Market cap $777.47MP/E –Yield –
Ardelyx, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 94.4%
- Operating margin
- -7.9%
- Net margin
- -12.4%
- Return on equity, FY2025
- -36.2%
Financial strength
- Current ratio
- 3.34
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 73.5%
Valuation
- P/E ratio
- –
- Price to sales
- 1.72
- Price to book
- 5.22
- Dividend yield
- –
See a number that looks wrong?